ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

COLL vs HELP // DIVIDEND YIELD & FCF PAYOUT SAFETY

Collegium Pharmaceutical Inc. (NASDAQ) VS. Helus Pharma Inc. (NASDAQ) • 15-METRIC TALLY: COLL 1 — HELP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. HELP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC COLL HELP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 59.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation 3.0x — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin 23.00% — — TIE /operating-margins <GO>
Net Profit Margin 8.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 23.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.27 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.9 44.7 +12.20 COLL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 10.4x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $782.3M $782.5M -$179.3K HELP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR COLL REV HELP REV COLL GROSS % HELP GROSS % COLL FCF HELP FCF
FY 2025 $780.6M — 59.3% — $327.6M —
FY 2024 $631.4M — 59.8% — $203.3M —
FY 2023 $566.8M — — — $274.7M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
HELP // BETA —